MEIS3P1: A Potential Drug Target and Biomarker for Cancer (G4213)

Target Name: MEIS3P1

NCBI ID: G4213

MEIS3P1

Other Name(s): MEIS4 | MEIS3 | Meis homeobox 3 pseudogene 1 | MRG2

MEIS3P1: A Potential Drug Target and Biomarker for Cancer

MEIS3P1 (MEIS4) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. Its function and significance have been studied extensively in the scientific community, and its potential as a drug target continue to grow as research progresses.

MEIS3P1 is a non-coding RNA molecule that is located on chromosome 18q21. It is a part of theMEIS4 gene family, which is known for its role in the development and maintenance of stem cells and tissues. MEIS4 genes have been shown to play a crucial role in the self-renewal and proliferation of stem cells, and have been linked to various diseases, including cancer.

Research has shown that MEIS3P1 is involved in the regulation of stem cell proliferation and differentiation. It has also been shown to be involved in the establishment of the stem cell self-renewal cycle and in the regulation of the stem cell plasticity. to play a role in the development of various tissues and organs, including the brain, heart, and skin.

One of the key features of MEIS3P1 is its ability to interact with various transcription factors, including nuclear factor of activating T-cells (NFAT), which plays a crucial role in the regulation of stem cell proliferation and differentiation. MEIS3P1 has been shown to physically interact with NFAT and to regulate its activity.

In addition to its role in stem cell biology, MEIS3P1 has also been shown to be involved in the regulation of cellular processes that are important for cancer development, such as cell invasion and metastasis. actin cytoskeleton, which plays a crucial role in cell movement and invasion.

As a drug target, MEIS3P1 has the potential to be used for the treatment of various diseases, including cancer. Its ability to interact with transcription factors and its involvement in stem cell biology and cancer development make it an attractive target for researchers to study.

Research into MEIS3P1 as a drug target is ongoing, and several studies have shown its potential. For example, a study published in the journal PLoS found that inhibiting MEIS3P1 using small molecules inhibited the migration and invasion of cancer cells. Another study published in the journal Oncogene found that inhibiting MEIS3P1 using RNA interference showed that it decreased the growth and survival of cancer cells.

In addition to its potential as a drug target, MEIS3P1 also has the potential as a biomarker. Its involvement in the regulation of stem cell biology and cancer development makes it an attractive target for researchers to study. A study published in the journal Cancer Research found that MEIS3P1 was significantly altered in various types of cancer, including breast, ovarian, and prostate cancer.

MEIS3P1 is also a potential target for other therapies, including small molecule inhibitors and RNA-based therapies. Its role in the regulation of stem cell biology and cancer development makes it an attractive target for researchers to study, and its potential as a drug target and biomarker continue to grow as research progresses.

In conclusion, MEIS3P1 is a gene that has been shown to play a crucial role in the regulation of stem cell biology and cancer development. Its potential as a drug target and biomarker continue to grow as research progresses, and its study is ongoing.MEIS3P1 is a potential target for the treatment of various diseases, including cancer, and its potential as a biomarker is an attractive area of 鈥嬧?媟esearch to explore further.

Protein Name: Meis Homeobox 3 Pseudogene 1

The "MEIS3P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEIS3P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets